What do systematic reviews say?

Multidisciplinary disease management programmes vs usual care

Multidisciplinary disease management programmes probably leads to lower all‐cause mortality compared with usual care (moderate certainty).

• Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
  RR 0.67 [0.54, 0.83]
  8 studies · 1764 participants
  Moderate

Case management vs usual care

Case management may leads to lower all‐cause mortality compared with usual care (low certainty).

• Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
  RR 0.78 [0.68, 0.9]
  26 studies · 6903 participants
  Low

Clinic‐based intervention vs usual care

Clinic‐based intervention showed no clear difference in all‐cause mortality compared with usual care (low certainty).

• Disease management interventions for heart failure 2019 · Cochrane Headline outcomes only
  RR 0.87 [0.68, 1.1]
  7 studies · 1686 participants
  Low

Carvedilol vs placebo

It is very uncertain whether carvedilol changes all‐cause mortality compared with placebo (very low certainty).

• Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
  RR 0.69 [0.12, 3.88]
  2 studies · 69 participants
  Very low

Rosuvastatin vs placebo

• Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 39 participants
  GRADE not reported

Amiodarone vs other antiarrhythmics

Amiodarone showed no clear difference in all‐cause mortality compared with other antiarrhythmics (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 1.03 [0.75, 1.42]
  5 studies · 898 participants
  Low

Amiodarone vs beta‐blocker

It is very uncertain whether amiodarone changes all‐cause mortality compared with beta blockers (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.7, 1.32]
  1 study · 189 participants
  Very low

Amiodarone vs sotalol

It is very uncertain whether amiodarone changes all‐cause mortality compared with sotalol (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 1.08 [0.41, 2.83]
  2 studies · 104 participants
  Very low

Amiodarone vs placebo or no treatment

Amiodarone showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.88 [0.78, 1]
  17 studies · 8383 participants
  Low

Amiodarone vs beta‐blocker

Amiodarone may leads to lower all‐cause mortality compared with beta blockers (low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.27 [0.1, 0.75]
  2 studies · 342 participants
  Low

Amiodarone vs other antiarrhythmics

Amiodarone probably leads to lower all‐cause mortality compared with other antiarrhythmics (moderate certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 0.37 [0.18, 0.76]
  3 studies · 540 participants
  Moderate

Amiodarone vs placebo or no treatment

It is very uncertain whether amiodarone changes all‐cause mortality compared with placebo or no treatment (very low certainty).

• Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death 2015 · Cochrane Headline outcomes only
  RR 3.05 [1.33, 7.01]
  2 studies · 440 participants
  Very low

Pharmacological treatment vs placebo

It is very uncertain whether summary of findings table ‐ Pharmacological treatment changes all‐cause mortality ‐ short term compared with placebo (very low certainty).

• Psychological and pharmacological interventions for depression in patients with coronary artery disease 2021 · Cochrane Headline outcomes only
  OR 0.38 [0.1, 1.47]
  2 studies · 437 participants
  Very low

Summary of findings table ‐ Psychological interventions vs control

It is very uncertain whether summary of findings table ‐ Psychological treatment changes all‐cause mortality ‐ short‐term compared with control (very low certainty).

• Psychological and pharmacological interventions for depression in patients with coronary artery disease 2021 · Cochrane Headline outcomes only
  OR 0.31 [0.05, 2.02]
  2 studies · 324 participants
  Very low

Pharmacological treatment vs pharmacological treatment 2

It is very uncertain whether summary of findings table ‐ Pharmacological treatment 1 changes all‐cause mortality ‐ short term (end of treatment) compared with pharmacological treatment 2 (very low certainty).

• Psychological and pharmacological interventions for depression in patients with coronary artery disease 2021 · Cochrane Headline outcomes only
  OR 2.72 [0.51, 14.49]
  1 study · 149 participants
  Very low

Psychological interventions vs psychological treatment

The review found no eligible studies for this question.

• Psychological and pharmacological interventions for depression in patients with coronary artery disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found